Aurobindo Pharma is currently trading at Rs. 255.40, up by 17.05 points or 7.15 % from its previous closing of Rs. 238.35 on the BSE.
The scrip opened at Rs. 246.90 and has touched a high and low of Rs. 258.60 and Rs. 244.50 respectively. So far 1884789 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 245.75 on 07-Nov-2013 and a 52 week low of Rs. 127.15 on 28-Mar-2013.
Last one week high and low of the scrip stood at Rs. 245.75 and Rs. 217.00 respectively. The current market cap of the company is Rs. 7421.52 crore.
The promoters holding in the company stood at 54.84 % while Institutions and Non-Institutions held 31.34 % and 13.82 % respectively.
Aurobindo Pharma has reported results for the second quarter ended September 30, 2013.
The company has reported 24.50% fall in its net profit at Rs 179.70 crore for the quarter as compared to Rs 238.01 crore for the same quarter in the previous year. However, total income of the company has increased by 14.49% at Rs 1600.05 crore for quarter under review as compared to Rs 1397.49 crore for the quarter ended September 30, 2012.
On the consolidated basis, the group has registered a growth of 5.67% in net profit after taxes and minority interest of Rs 234.95 crore as compared to Rs 222.35 crore in the same quarter previous year. Total income of the group rose 27.33% to Rs 1918.97 crore for quarter under review as against Rs 1507.03 crore in corresponding quarter previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: